Share |
News

Verisante Joins Frankfurt Stock Exchange


July 21, 2011 at 7:30 pm

Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that the Company has begun trading on the Frankfurt Stock Exchange, one of the world’s largest trading centres for securities. 


"Verisante is steadily moving towards obtaining a CE Mark by the end of the year, which will allow us to begin marketing the Aura™ device for skin cancer detection in Europe,” said Thomas Braun, President and CEO.  “Europe is a major market for the Aura with 21,000 dermatologists and 450,000 general practitioners.  We will be attending conferences and trade shows in Europe and listing on the Frankfurt Exchange makes sense as investor awareness will emerge as a result of our product advertising and marketing efforts.”

Investors can find current financial disclosure and Real-Time quotes for Verisante’s equities on http://www.boerse-frankfurt.de under the Stock Symbol V3T (or ISIN CA92346G1046).


Investors can also find the Company’s corporate video and Zacks Investment Analyst reports on the Company’s website at www.verisante.com.


About the Frankfurt Stock Exchange

The Frankfurt Stock Exchange was founded almost 400 years ago and today hosts companies from over 80 countries.  It is one of the world's largest trading centres for securities. 

The FSE accounts for over 90 percent of the turnover in the German market, a higher turnover velocity than the London exchange, and it is the largest of Germany's seven stock exchanges.  It is also third in terms of volume, just behind New York and NASDAQ.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most

 
common cancers.  The Aura and Core have not yet been approved for sale.  The Company anticipates Health Canada approval for the Aura in late 2011.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

Verisante Technology, Inc.
Thomas Braun, President & CEO   
Telephone: (604) 605-0507

Email: info@verisante.com
Website:  www.verisante.com
Youtube:  www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top